Laboratorios Richmond S.A.C.I.F
Buy or Sell?

I guess you are interested in Laboratorios Richmond S.A.C.I.F. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Laboratorios Richmond S.A.C.I.F Daily Candlestick Chart

Let's start. I'm going to help you getting a better view of Laboratorios Richmond S.A.C.I.F. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Laboratorios Richmond S.A.C.I.F even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Laboratorios Richmond S.A.C.I.F is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Laboratorios Richmond S.A.C.I.F. The closing price on 2022-06-24 was ARS238.00 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.

1.1. Profitability of Laboratorios Richmond S.A.C.I.F.

An important factor of a company's health is the profitability.

1.1.1. Net Profit Margin of Laboratorios Richmond S.A.C.I.F.

One of the most important indicator to determine the financial health of a company is the Net Profit Margin. What is the net profit from the generated revenue? A healthy Net Profit Margin is higher than 10%.

PeriodLaboratorios Richmond S.A.C.I.FDrug Manufacturers-Specialty & Generic (mean)Drug Manufacturers-Specialty & Generic (average)
MRQ8.7%2.2%-423.9%
TTM0.9%1.5%-43,400.5%
YOY6.3%2.4%-6,664.9%
5Y1.2%0.6%-11,269.3%
10Y2.4%1.3%-7,239.8%

Let's take a look of the Net Profit Margin trends of Laboratorios Richmond S.A.C.I.F:

  • The MRQ is 8.7%. Neutral. Compare to industry.
  • The TTM is 0.9%. Very low, is it enough? Compare to industry. -1
  • The TTM is 0.9%. Compared to the MRQ, the short term is trending up. +1
  • The YOY is 6.3%. Compared to the TTM, the mid term is trending down. -1
  • The 5Y is 1.2%. Compared to the TTM, the 5Y term is trending down. -1
  • The 10Y is 2.4%. Compared to the 5Y term, the 10Y term is trending down. -1

Let's compare the company's Net Profit Margin with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:

  • The MRQ average (mean) in the Drug Manufacturers-Specialty & Generic industry is 2.2%. The company's MRQ (8.7%) is outperforming the industry with 6.5%. +1
  • The TTM average (mean) in the Drug Manufacturers-Specialty & Generic industry is 1.5%. The company's TTM (0.9%) is underperforming the industry with -0.6%. -1

1.1.2. Return On Assets of Laboratorios Richmond S.A.C.I.F.

A healthy Return On Assets is above 5%.

PeriodLaboratorios Richmond S.A.C.I.FDrug Manufacturers-Specialty & Generic (mean)Drug Manufacturers-Specialty & Generic (average)
MRQ2.7%0.4%-31.1%
TTM0.5%0.2%-5,075.2%
YOY1.6%0.2%-1,456.2%
5Y0.4%0.1%-1,385.0%
10Y0.8%0.3%-870.0%

Let's take a look of the Return On Assets trends of Laboratorios Richmond S.A.C.I.F:

  • The MRQ is 2.7%. Neutral. Compare to industry.
  • The TTM is 0.5%. Bad. -1
  • The TTM is 0.5%. Compared to the MRQ, the short term is trending up. +1
  • The YOY is 1.6%. Compared to the TTM, the mid term is trending down. -1
  • The 5Y is 0.4%. Compared to the TTM, the 5Y term is trending up. +1
  • The 10Y is 0.8%. Compared to the 5Y term, the 10Y term is trending down. -1

Let's compare the company's Return On Assets with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:

  • The MRQ average (mean) in the Drug Manufacturers-Specialty & Generic industry is 0.4%. The company's MRQ (2.7%) is outperforming the industry with 2.3%. +1
  • The TTM average (mean) in the Drug Manufacturers-Specialty & Generic industry is 0.2%. The company's TTM (0.5%) is outperforming the industry with 0.3%. +1

1.1.3. Return On Equity of Laboratorios Richmond S.A.C.I.F.

A healthy Return On Equity is above 15%.

PeriodLaboratorios Richmond S.A.C.I.FDrug Manufacturers-Specialty & Generic (mean)Drug Manufacturers-Specialty & Generic (average)
MRQ13.2%1.2%-10.9%
TTM2.7%0.8%-20,263.5%
YOY3.9%0.7%-38.9%
5Y1.7%0.3%-3,852.7%
10Y3.4%0.6%-1,919.9%

Let's take a look of the Return On Equity trends of Laboratorios Richmond S.A.C.I.F:

  • The MRQ is 13.2%. Neutral. Compare to industry.
  • The TTM is 2.7%. Bad. -1
  • The TTM is 2.7%. Compared to the MRQ, the short term is trending up. +1
  • The YOY is 3.9%. Compared to the TTM, the mid term is trending down. -1
  • The 5Y is 1.7%. Compared to the TTM, the 5Y term is trending up. +1
  • The 10Y is 3.4%. Compared to the 5Y term, the 10Y term is trending down. -1

Let's compare the company's Return On Equity with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:

  • The MRQ average (mean) in the Drug Manufacturers-Specialty & Generic industry is 1.2%. The company's MRQ (13.2%) is outperforming the industry with 12.0%. +1
  • The TTM average (mean) in the Drug Manufacturers-Specialty & Generic industry is 0.8%. The company's TTM (2.7%) is outperforming the industry with 1.9%. +1

1.2. Operating Efficiency of Laboratorios Richmond S.A.C.I.F.

1.2.1. Operating Margin of Laboratorios Richmond S.A.C.I.F.

A healthy Operating Margin is above 15%.

PeriodLaboratorios Richmond S.A.C.I.FDrug Manufacturers-Specialty & Generic (mean)Drug Manufacturers-Specialty & Generic (average)
MRQ-4.9%-326.8%
TTM13.7%2.8%-37,528.8%
YOY21.0%4.1%8,834.9%
5Y8.4%3.1%-4,596.1%
10Y4.7%2.0%-1,187.8%

Let's take a look of the Operating Margin trends of Laboratorios Richmond S.A.C.I.F:

  • The MRQ is 0.0%. The data is not here.
  • The YOY is 21.0%. Compared to the TTM, the mid term is trending down. -1
  • The 5Y is 8.4%. Compared to the TTM, the 5Y term is trending up. +1
  • The 10Y is 4.7%. Compared to the 5Y term, the 10Y term is trending up. +1

Let's compare the company's Operating Margin with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:

  • The MRQ average (mean) in the Drug Manufacturers-Specialty & Generic industry is 4.9%. The company's MRQ (0.0%) is underperforming the industry with -4.9%. -1
  • The TTM average (mean) in the Drug Manufacturers-Specialty & Generic industry is 2.8%. The company's TTM (13.7%) is outperforming the industry with 10.9%. +1

1.2.2. Operating Ratio of Laboratorios Richmond S.A.C.I.F.

A healthy Operating Ratio is below 1.

PeriodLaboratorios Richmond S.A.C.I.FDrug Manufacturers-Specialty & Generic (mean)Drug Manufacturers-Specialty & Generic (average)
MRQ1.5561.3823.673
TTM1.4771.3611,600.776
YOY1.2671.373-87.241
5Y1.0741.318277.684
10Y0.8091.147130.843

Let's take a look of the Operating Ratio trends of Laboratorios Richmond S.A.C.I.F:

  • The MRQ is 1.556. Very good. +2
  • The TTM is 1.477. Very good. +2
  • The TTM is 1.477. Compared to the MRQ, the short term is trending up. -1
  • The YOY is 1.267. Compared to the TTM, the mid term is trending up. -1
  • The 5Y is 1.074. Compared to the TTM, the 5Y term is trending up. -1
  • The 10Y is 0.809. Compared to the 5Y term, the 10Y term is trending up. -1

Let's compare the company's Operating Ratio with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:

  • The MRQ average (mean) in the Drug Manufacturers-Specialty & Generic industry is 1.382. The company's MRQ (1.556) is underperforming the industry with 0.174. -1
  • The TTM average (mean) in the Drug Manufacturers-Specialty & Generic industry is 1.361. The company's TTM (1.477) is underperforming the industry with 0.116. -1

1.3. Liquidity of Laboratorios Richmond S.A.C.I.F.

1.3.1. Current Ratio of Laboratorios Richmond S.A.C.I.F.

A healthy Current Ratio is above 1.

PeriodLaboratorios Richmond S.A.C.I.FDrug Manufacturers-Specialty & Generic (mean)Drug Manufacturers-Specialty & Generic (average)
MRQ1.6552.0113.916
TTM1.3822.0493.587
YOY1.3462.0933.306
5Y0.8992.1215.082
10Y0.4991.8434.686

Let's take a look of the Current Ratio trends of Laboratorios Richmond S.A.C.I.F:

  • The MRQ is 1.655. Good. +1
  • The TTM is 1.382. Neutral. Compare to industry.
  • The TTM is 1.382. Compared to the MRQ, the short term is trending up. +1
  • The YOY is 1.346. Compared to the TTM, the mid term is trending up. +1
  • The 5Y is 0.899. Compared to the TTM, the 5Y term is trending up. +1
  • The 10Y is 0.499. Compared to the 5Y term, the 10Y term is trending up. +1

Let's compare the company's Current Ratio with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:

  • The MRQ average (mean) in the Drug Manufacturers-Specialty & Generic industry is 2.011. The company's MRQ (1.655) is underperforming the industry with -0.356. -1
  • The TTM average (mean) in the Drug Manufacturers-Specialty & Generic industry is 2.049. The company's TTM (1.382) is underperforming the industry with -0.667. -1

1.3.2. Quick Ratio of Laboratorios Richmond S.A.C.I.F.

A healthy Quick Ratio is above 1.

PeriodLaboratorios Richmond S.A.C.I.FDrug Manufacturers-Specialty & Generic (mean)Drug Manufacturers-Specialty & Generic (average)
MRQ0.6680.7312.207
TTM0.5230.8342.206
YOY0.7450.8041.933
5Y0.6470.8351.881
10Y0.6910.8121.806

Let's take a look of the Quick Ratio trends of Laboratorios Richmond S.A.C.I.F:

  • The MRQ is 0.668. Warning. Indication that company may not be able to fully pay off its current liabilities in the short term. -1
  • The TTM is 0.523. Warning. Indication that company may not be able to fully pay off its current liabilities in the short term. -1
  • The TTM is 0.523. Compared to the MRQ, the short term is trending up. +1
  • The YOY is 0.745. Compared to the TTM, the mid term is trending down. -1
  • The 5Y is 0.647. Compared to the TTM, the 5Y term is trending down. -1
  • The 10Y is 0.691. Compared to the 5Y term, the 10Y term is trending down. -1

Let's compare the company's Quick Ratio with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:

  • The MRQ average (mean) in the Drug Manufacturers-Specialty & Generic industry is 0.731. The company's MRQ (0.668) is underperforming the industry with -0.063. -1
  • The TTM average (mean) in the Drug Manufacturers-Specialty & Generic industry is 0.834. The company's TTM (0.523) is underperforming the industry with -0.311. -1

1.4. Solvency of Laboratorios Richmond S.A.C.I.F.

1.4.1. Total-Debt-to-Total-Assets Ratio of Laboratorios Richmond S.A.C.I.F.

A healthy Total-Debt-to-Total-Assets Ratio is below 1.

PeriodLaboratorios Richmond S.A.C.I.FDrug Manufacturers-Specialty & Generic (mean)Drug Manufacturers-Specialty & Generic (average)
MRQ0.7910.4125.044
TTM0.7180.4115.946
YOY0.5910.39624.438
5Y0.6490.3969.475
10Y0.6980.4009.057

Let's take a look of the Total-Debt-to-Total-Assets Ratio trends of Laboratorios Richmond S.A.C.I.F:

  • The MRQ is 0.791. Tight, but oke.
  • The TTM is 0.718. Healty. +1
  • The TTM is 0.718. Compared to the MRQ, the short term is trending up. -1
  • The YOY is 0.591. Compared to the TTM, the mid term is trending up. -1
  • The 5Y is 0.649. Compared to the TTM, the 5Y term is trending up. -1
  • The 10Y is 0.698. Compared to the 5Y term, the 10Y term is trending down. +1

Let's compare the company's Total-Debt-to-Total-Assets Ratio with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:

  • The MRQ average (mean) in the Drug Manufacturers-Specialty & Generic industry is 0.412. The company's MRQ (0.791) is underperforming the industry with 0.379. -1
  • The TTM average (mean) in the Drug Manufacturers-Specialty & Generic industry is 0.411. The company's TTM (0.718) is underperforming the industry with 0.307. -1

1.4.2. Debt-To-Equity Ratio of Laboratorios Richmond S.A.C.I.F.

A healthy Debt-To-Equity Ratio is below 2.

PeriodLaboratorios Richmond S.A.C.I.FDrug Manufacturers-Specialty & Generic (mean)Drug Manufacturers-Specialty & Generic (average)
MRQ3.8380.6252.583
TTM3.0090.6602.312
YOY1.4750.6242.751
5Y2.1480.6641.949
10Y2.7030.6881.750

Let's take a look of the Debt-To-Equity Ratio trends of Laboratorios Richmond S.A.C.I.F:

  • The MRQ is 3.838. Bad. To much debt compared to equity. -1
  • The TTM is 3.009. Bad. To much debt compared to equity. -1
  • The TTM is 3.009. Compared to the MRQ, the short term is trending up. -1
  • The YOY is 1.475. Compared to the TTM, the mid term is trending up. -1
  • The 5Y is 2.148. Compared to the TTM, the 5Y term is trending up. -1
  • The 10Y is 2.703. Compared to the 5Y term, the 10Y term is trending down. +1

Let's compare the company's Debt-To-Equity Ratio with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:

  • The MRQ average (mean) in the Drug Manufacturers-Specialty & Generic industry is 0.625. The company's MRQ (3.838) is underperforming the industry with 3.213. -1
  • The TTM average (mean) in the Drug Manufacturers-Specialty & Generic industry is 0.660. The company's TTM (3.009) is underperforming the industry with 2.349. -1

2. Market Valuation of Laboratorios Richmond S.A.C.I.F.

2.1. Price-to-Earnings Ratio of Laboratorios Richmond S.A.C.I.F.

A Price-to-Earnings Ratio above 15 may indicate an overpriced stock. However this is very hard to determine. Best way is to compare the PE Ratio with the industry average.

PeriodLaboratorios Richmond S.A.C.I.FDrug Manufacturers-Specialty & Generic (mean)Drug Manufacturers-Specialty & Generic (average)
EOD-182.7040.4100.584
MRQ-170.4211.141-3.303
TTM0.1011.00117.337
YOY32.2733.073-83.308
5Y1.9125.909-127.348
10Y1.0627.016-147.432

Let's take a look of the Price-to-Earnings Ratio trends of Laboratorios Richmond S.A.C.I.F:

  • The EOD is -182.704. Company is losing money. -2
  • The MRQ is -170.421. Company is losing money. -2
  • The TTM is 0.101. Very good. +2
  • The TTM is 0.101. Compared to the MRQ, the short term is trending down. +1
  • The YOY is 32.273. Compared to the TTM, the mid term is trending down. +1
  • The 5Y is 1.912. Compared to the TTM, the 5Y term is trending down. +1
  • The 10Y is 1.062. Compared to the 5Y term, the 10Y term is trending up. -1

Let's compare the company's Price-to-Earnings Ratio with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:

  • The MRQ average (mean) in the Drug Manufacturers-Specialty & Generic industry is 1.141. The company's MRQ (-170.421) is outperforming the industry with -171.562. +1
  • The TTM average (mean) in the Drug Manufacturers-Specialty & Generic industry is 1.001. The company's TTM (0.101) is outperforming the industry with -0.900. +1

2.2. Price/Earnings-to-Growth Ratio of Laboratorios Richmond S.A.C.I.F.

PeriodLaboratorios Richmond S.A.C.I.FDrug Manufacturers-Specialty & Generic (mean)Drug Manufacturers-Specialty & Generic (average)
MRQ787.7611.089-224.992
TTM241.9810.041110.620
YOY-8.3453.35112,755.229
5Y116.8187.42417,111.564
10Y116.8187.75811,093.204

Let's take a look of the Price/Earnings-to-Growth Ratio trends of Laboratorios Richmond S.A.C.I.F:

  • The MRQ is 787.761. Seems overpriced? -1
  • The TTM is 241.981. Seems overpriced? -1
  • The TTM is 241.981. Compared to the MRQ, the short term is trending up. -1
  • The YOY is -8.345. Compared to the TTM, the mid term is trending up. -1
  • The 5Y is 116.818. Compared to the TTM, the 5Y term is trending up. -1
  • The 10Y is 116.818. Compared to the 5Y term, the 10Y term is not trending.

Let's compare the company's Price/Earnings-to-Growth Ratio with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:

  • The MRQ average (mean) in the Drug Manufacturers-Specialty & Generic industry is 1.089. The company's MRQ (787.761) is underperforming the industry with 786.672. -1
  • The TTM average (mean) in the Drug Manufacturers-Specialty & Generic industry is 0.041. The company's TTM (241.981) is underperforming the industry with 241.940. -1

2.3. Price-to-Book Ratio of Laboratorios Richmond S.A.C.I.F.

A healthy Price-to-Book Ratio is below 3.

PeriodLaboratorios Richmond S.A.C.I.FDrug Manufacturers-Specialty & Generic (mean)Drug Manufacturers-Specialty & Generic (average)
EOD3.5751.63758.918
MRQ3.3351.926162.075
TTM4.0862.19751.679
YOY3.2992.274299.576
5Y2.1532.03479.132
10Y1.1961.57377.620

Let's take a look of the Price-to-Book Ratio trends of Laboratorios Richmond S.A.C.I.F:

  • The EOD is 3.575. Neutral. Compare to industry.
  • The MRQ is 3.335. Neutral. Compare to industry.
  • The TTM is 4.086. Neutral. Compare to industry.
  • The TTM is 4.086. Compared to the MRQ, the short term is trending down. +1
  • The YOY is 3.299. Compared to the TTM, the mid term is trending up. -1
  • The 5Y is 2.153. Compared to the TTM, the 5Y term is trending up. -1
  • The 10Y is 1.196. Compared to the 5Y term, the 10Y term is trending up. -1

Let's compare the company's Price-to-Book Ratio with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:

  • The MRQ average (mean) in the Drug Manufacturers-Specialty & Generic industry is 1.926. The company's MRQ (3.335) is underperforming the industry with 1.409. -1
  • The TTM average (mean) in the Drug Manufacturers-Specialty & Generic industry is 2.197. The company's TTM (4.086) is underperforming the industry with 1.889. -1

3.1. Key Performance Indicators

The key performance indicators of Laboratorios Richmond S.A.C.I.F compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Per Share--66.57054.255+23%33.132+101%21.125+215%11.736+467%
Current Ratio--1.6551.382+20%1.346+23%0.899+84%0.499+231%
Debt To Asset Ratio--0.7910.718+10%0.591+34%0.649+22%0.698+13%
Debt To Equity Ratio--3.8383.009+28%1.475+160%2.148+79%2.703+42%
Eps----0.3260%1.505-100%0.308-100%0.171-100%
Gross Profit Margin--1.0001.0000%1.0000%0.950+5%0.833+20%
Net Profit Margin--0.0870.009+821%0.063+39%0.012+608%0.024+257%
Operating Margin---0.137-100%0.210-100%0.084-100%0.047-100%
Operating Ratio--1.5561.477+5%1.267+23%1.074+45%0.809+92%
Pb Ratio3.575+7%3.3354.086-18%3.299+1%2.153+55%1.196+179%
Pe Ratio-182.704-7%-170.4210.101-168964%32.273-628%1.912-9015%1.062-16146%
Peg Ratio--787.761241.981+226%-8.345+101%116.818+574%116.818+574%
Price Per Share238.000+7%222.000219.500+1%107.438+107%86.063+158%47.813+364%
Quick Ratio--0.6680.523+28%0.745-10%0.647+3%0.691-3%
Return On Assets--0.0270.005+438%0.016+71%0.004+540%0.008+246%
Return On Equity--0.1320.027+389%0.039+234%0.017+687%0.034+284%
 EOD+1 -2MRQTTM+8 -6YOY+6 -95Y+8 -810Y+7 -9

3.2. Fundamental Score

Let's check the fundamental score of Laboratorios Richmond S.A.C.I.F based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
PE Ratio (EOD)Between0-15-182.704
PB Ratio (EOD)Between0-13.575
Net Profit Margin (MRQ)Greater than00.087
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.668
Current Ratio (MRQ)Greater than11.655
Debt Ratio (MRQ)Less than10.791
DE Ratio (MRQ)Less than13.838
ROE (MRQ)Greater than0.150.132
ROA (MRQ)Greater than0.050.027
Total3/10 (30.0%)

Create your own Stock Scanner

Investing is personal. The best investors buy stocks based on their own analysis. Create your personal Stock Scanner with the key performance indicators that are important to you.
Create your own Stock Scanner


3.3. Technical Score

Let's check the technical score of Laboratorios Richmond S.A.C.I.F based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.092
Ma 20Greater thanMa 50238.613
Ma 50Greater thanMa 100237.075
Ma 100Greater thanMa 200241.140
OpenGreater thanClose235.000
Total2/5 (40.0%)

Create your own Symbol Scanner

Trading is personal. The best traders buy and sell based on their own technical analysis. Create your personal Symbol Scanner with the technical indicators that are important to you.
Create your own Symbol Scanner




Latest Balance Sheet

Balance Sheet of 2021-12-31. Currency in ARS. All numbers in thousands.

Summary
Total Assets25,693,158
Total Liabilities20,317,526
Total Stockholder Equity5,293,621
 As reported
Total Liabilities 20,317,526
Total Stockholder Equity+ 5,293,621
Total Assets = 25,693,158

Assets

Total Assets25,693,158
Total Current Assets15,434,862
Long-term Assets15,434,862
Total Current Assets
Cash And Cash Equivalents 4,666,788
Short-term Investments 2,693,158
Net Receivables 3,532,618
Inventory 3,824,574
Total Current Assets  (as reported)15,434,862
Total Current Assets  (calculated)14,717,138
+/- 717,724
Long-term Assets
Goodwill 531,171
Intangible Assets 1,462,932
Long-term Assets  (as reported)10,258,296
Long-term Assets  (calculated)1,994,102
+/- 8,264,193

Liabilities & Shareholders' Equity

Total Current Liabilities9,326,184
Long-term Liabilities10,991,342
Total Stockholder Equity5,293,621
Total Current Liabilities
Short Long Term Debt 1,788,036
Accounts payable 5,724,387
Other Current Liabilities 30,000
Total Current Liabilities  (as reported)9,326,184
Total Current Liabilities  (calculated)7,542,424
+/- 1,783,760
Long-term Liabilities
Long term Debt 1,187,600
Capital Lease Obligations Min Short Term Debt146,125
Long-term Liabilities Other 12,302
Long-term Liabilities  (as reported)10,991,342
Long-term Liabilities  (calculated)1,346,028
+/- 9,645,315
Total Stockholder Equity
Retained Earnings 591,464
Total Stockholder Equity (as reported)5,293,621
Total Stockholder Equity (calculated)591,464
+/- 4,702,157
Other
Common Stock Shares Outstanding 80,751
Net Invested Capital 8,269,258
Net Working Capital 6,108,678



Balance Sheet

Currency in ARS. All numbers in thousands.

 Trend2021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312011-12-312010-12-312009-12-312008-12-312008-09-302007-09-302006-09-30
> Total Assets 
56,356
77,583
100,634
107,007
127,840
135,779
159,025
270,955
276,743
276,743
290,686
287,372
315,091
323,549
357,608
385,658
387,299
391,705
400,815
532,834
556,555
640,283
724,917
861,132
726,253
779,149
912,391
1,552,641
1,637,185
1,821,701
2,402,981
2,705,186
2,805,766
2,948,371
3,807,181
5,134,618
5,260,627
5,845,090
6,986,402
8,133,335
9,254,840
12,165,119
24,167,525
25,693,158
25,693,15824,167,52512,165,1199,254,8408,133,3356,986,4025,845,0905,260,6275,134,6183,807,1812,948,3712,805,7662,705,1862,402,9811,821,7011,637,1851,552,641912,391779,149726,253861,132724,917640,283556,555532,834400,815391,705387,299385,658357,608323,549315,091287,372290,686276,743276,743270,955159,025135,779127,840107,007100,63477,58356,356
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,967,306
1,914,169
1,894,278
2,571,194
3,287,659
3,263,874
3,591,461
4,519,380
5,371,511
5,406,240
7,750,533
10,771,693
15,434,862
15,434,86210,771,6937,750,5335,406,2405,371,5114,519,3803,591,4613,263,8743,287,6592,571,1941,894,2781,914,1691,967,3060000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
501,119
347,465
258,089
350,686
217,146
310,788
500,976
315,168
493,831
516,623
404,284
1,597,793
4,666,788
4,666,7881,597,793404,284516,623493,831315,168500,976310,788217,146350,686258,089347,465501,1190000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
481
799
1,148
3,668
1,720
1,188
1,085
357,776
345,707
347,005
532,356
85,949
2,693,158
2,693,15885,949532,356347,005345,707357,7761,0851,1881,7203,6681,1487994810000000000000000000000000000000
       Net Receivables 
16,278
24,723
24,876
27,233
31,007
35,816
46,019
96,359
105,744
105,744
114,664
111,643
126,968
134,815
156,568
192,546
180,550
185,857
173,047
267,087
262,666
267,879
311,128
498,253
338,047
329,962
406,844
512,300
653,201
690,781
885,401
785,003
616,057
678,506
958,190
1,959,409
1,852,293
1,672,216
2,159,626
2,936,487
1,925,213
2,691,864
2,496,087
3,532,618
3,532,6182,496,0872,691,8641,925,2132,936,4872,159,6261,672,2161,852,2931,959,409958,190678,506616,057785,003885,401690,781653,201512,300406,844329,962338,047498,253311,128267,879262,666267,087173,047185,857180,550192,546156,568134,815126,968111,643114,664105,744105,74496,35946,01935,81631,00727,23324,87624,72316,278
       Other Current Assets 
918
888
15,252
16,553
13,310
953
606
498
0
0
0
0
0
0
0
0
0
0
0
4,546
18,756
9,874
14,311
14,666
11,873
12,404
24,376
12,994
28,038
32,646
20,857
150,080
180,388
124,871
172,835
178,477
197,338
248,894
421,935
287,748
546,618
1,191,245
372,305
0
0372,3051,191,245546,618287,748421,935248,894197,338178,477172,835124,871180,388150,08020,85732,64628,03812,99424,37612,40411,87314,66614,3119,87418,7564,5460000000000049860695313,31016,55315,252888918
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
891,597
1,054,093
1,235,987
1,846,959
1,996,753
2,253,630
2,467,021
3,168,386
3,848,600
4,414,586
13,395,832
10,258,296
10,258,29613,395,8324,414,5863,848,6003,168,3862,467,0212,253,6301,996,7531,846,9591,235,9871,054,093891,59700000000000000000000000000000000
       Property Plant Equipment 
13,126
20,344
22,083
22,179
22,918
37,995
44,800
52,499
0
0
0
52,549
52,428
0
54,516
54,525
53,702
54,699
53,642
55,316
55,560
55,322
56,996
58,306
67,184
70,593
71,867
91,973
91,649
96,152
198,977
383,959
472,937
569,658
671,096
1,196,276
1,250,129
1,347,306
1,429,438
2,015,013
2,337,935
2,725,498
3,046,123
0
03,046,1232,725,4982,337,9352,015,0131,429,4381,347,3061,250,1291,196,276671,096569,658472,937383,959198,97796,15291,64991,97371,86770,59367,18458,30656,99655,32255,56055,31653,64254,69953,70254,52554,516052,42852,54900052,49944,80037,99522,91822,17922,08320,34413,126
       Goodwill 
0
0
0
0
0
0
0
40,438
0
0
0
31,420
30,973
0
30,079
29,632
29,184
28,737
28,290
31,420
31,420
31,420
31,420
31,420
31,420
31,420
39,783
32,339
32,248
32,609
33,121
143,669
178,636
193,533
221,859
245,929
287,113
304,512
328,063
300,277
409,657
449,661
486,155
531,171
531,171486,155449,661409,657300,277328,063304,512287,113245,929221,859193,533178,636143,66933,12132,60932,24832,33939,78331,42031,42031,42031,42031,42031,42031,42028,29028,73729,18429,63230,079030,97331,42000040,4380000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,692
4,101
5,355
5,500
4,218
0
0
0
0
0
0
0
0
000000004,2185,5005,3554,10111,6920000000000000000000000000000000
       Intangible Assets 
311
457
1,622
691
679
543
147
40,625
5,964
5,964
6,174
31,420
30,973
6,788
30,079
29,632
29,184
28,737
28,771
31,420
31,420
31,420
31,420
31,420
31,420
31,420
39,783
32,339
32,376
32,821
33,913
3,200
188,206
240,895
288,322
335,738
379,915
421,531
508,649
623,643
804,240
975,114
1,128,651
1,462,932
1,462,9321,128,651975,114804,240623,643508,649421,531379,915335,738288,322240,895188,2063,20033,91332,82132,37632,33939,78331,42031,42031,42031,42031,42031,42031,42028,77128,73729,18429,63230,0796,78830,97331,4206,1745,9645,96440,6251475436796911,622457311
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
891,597
1,054,093
1,235,987
0
0
0
0
0
0
0
0
0
0000000001,235,9871,054,093891,59700000000000000000000000000000000
> Total Liabilities 
48,610
64,334
71,342
68,621
74,108
90,962
108,921
178,942
185,468
185,468
207,433
196,336
235,531
243,608
274,160
292,642
299,363
300,866
303,726
436,712
460,578
540,743
605,060
671,672
549,419
625,695
715,969
864,588
911,607
1,130,640
1,616,125
1,594,256
1,669,514
1,731,410
2,369,968
3,034,658
3,051,279
3,443,970
4,275,481
4,752,830
5,500,623
8,099,865
19,838,051
20,317,526
20,317,52619,838,0518,099,8655,500,6234,752,8304,275,4813,443,9703,051,2793,034,6582,369,9681,731,4101,669,5141,594,2561,616,1251,130,640911,607864,588715,969625,695549,419671,672605,060540,743460,578436,712303,726300,866299,363292,642274,160243,608235,531196,336207,433185,468185,468178,942108,92190,96274,10868,62171,34264,33448,610
   > Total Current Liabilities 
36,242
32,065
51,411
48,157
50,443
49,927
70,886
132,790
144,643
144,643
164,239
153,556
182,401
186,583
218,576
239,846
243,496
240,821
222,613
337,703
354,829
390,143
455,045
546,952
425,365
516,202
634,249
748,417
780,462
954,980
1,327,483
1,250,101
1,267,508
1,380,095
2,005,622
2,475,950
2,480,757
2,820,832
3,522,630
3,550,319
3,695,913
5,913,989
9,805,072
9,326,184
9,326,1849,805,0725,913,9893,695,9133,550,3193,522,6302,820,8322,480,7572,475,9502,005,6221,380,0951,267,5081,250,1011,327,483954,980780,462748,417634,249516,202425,365546,952455,045390,143354,829337,703222,613240,821243,496239,846218,576186,583182,401153,556164,239144,643144,643132,79070,88649,92750,44348,15751,41132,06536,242
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
302,330
341,545
340,886
449,337
346,659
0
0
0
0
0
0
0
0
00000000346,659449,337340,886341,545302,3300000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
302,330
341,545
340,886
449,337
346,659
325,998
566,163
987,993
659,873
632,373
1,871,833
2,090,837
1,788,036
1,788,0362,090,8371,871,833632,373659,873987,993566,163325,998346,659449,337340,886341,545302,3300000000000000000000000000000000
       Accounts payable 
33,502
27,105
43,601
40,415
36,735
25,200
36,272
72,066
63,494
63,494
68,286
55,509
82,352
79,388
100,744
102,671
116,583
109,532
105,153
161,772
177,376
189,468
195,173
225,076
190,964
280,531
365,272
375,389
373,387
530,682
833,245
857,549
854,992
967,806
1,428,534
1,861,857
1,905,383
2,028,514
2,226,285
2,360,382
2,721,935
3,739,832
6,263,583
5,724,387
5,724,3876,263,5833,739,8322,721,9352,360,3822,226,2852,028,5141,905,3831,861,8571,428,534967,806854,992857,549833,245530,682373,387375,389365,272280,531190,964225,076195,173189,468177,376161,772105,153109,532116,583102,671100,74479,38882,35255,50968,28663,49463,49472,06636,27225,20036,73540,41543,60127,10533,502
       Other Current Liabilities 
540
2,308
3,001
2,862
2,442
4,252
7,325
15,221
20,912
20,912
17,560
11,919
13,022
14,132
15,077
19,240
18,811
24,886
20,877
36,280
51,298
52,763
59,489
114,519
63,502
78,660
68,825
100,418
102,432
70,939
119,724
22,193
8
8,504
11,529
51,563
78,576
108,638
147,153
159,442
73,729
83,902
92,093
30,000
30,00092,09383,90273,729159,442147,153108,63878,57651,56311,5298,504822,193119,72470,939102,432100,41868,82578,66063,502114,51959,48952,76351,29836,28020,87724,88618,81119,24015,07714,13213,02211,91917,56020,91220,91215,2217,3254,2522,4422,8623,0012,308540
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
402,006
351,315
364,345
558,708
570,522
623,138
752,851
1,486,170
1,804,710
2,185,876
10,032,979
10,991,342
10,991,34210,032,9792,185,8761,804,7101,486,170752,851623,138570,522558,708364,345351,315402,00600000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-302,330
-341,545
-340,886
-449,337
-315,521
73,061
72,111
68,712
31,771
5,854
18
25,484
146,125
146,12525,484185,85431,77168,71272,11173,061-315,521-449,337-340,886-341,545-302,3300000000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
69,408
68,459
93,506
44,112
6,437
7,036
7,598
13,238
22,032
22,925
11,825
12,302
12,30211,82522,92522,03213,2387,5987,0366,43744,11293,50668,45969,40800000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
140,103
183,662
235,836
282,143
327,755
372,981
414,059
501,529
647,600
796,149
967,297
1,120,985
0
01,120,985967,297796,149647,600501,529414,059372,981327,755282,143235,836183,662140,1030000000000000000000000000000000
> Total Stockholder Equity
7,746
13,245
29,288
38,381
53,727
44,815
50,110
91,953
91,274
91,274
83,253
91,036
79,560
79,941
83,447
93,016
87,937
90,839
97,089
96,121
95,976
99,540
119,858
189,460
176,834
153,454
196,421
688,053
708,993
667,279
709,077
1,051,302
1,105,404
1,181,850
1,389,902
2,050,207
2,155,494
2,347,810
2,655,308
3,380,506
3,681,875
3,990,315
4,245,571
5,293,621
5,293,6214,245,5713,990,3153,681,8753,380,5062,655,3082,347,8102,155,4942,050,2071,389,9021,181,8501,105,4041,051,302709,077667,279708,993688,053196,421153,454176,834189,460119,85899,54095,97696,12197,08990,83987,93793,01683,44779,94179,56091,03683,25391,27491,27491,95350,11044,81553,72738,38129,28813,2457,746
   Common Stock
133
2,822
2,822
3,642
3,642
27,254
27,254
27,254
66,584
66,584
66,584
27,254
27,254
66,584
27,254
27,254
27,254
27,254
27,254
27,254
27,254
27,254
27,254
27,254
66,584
66,584
66,584
80,752
80,752
80,752
80,752
80,751
80,751
80,751
80,751
80,751
80,751
80,751
80,751
80,751
80,751
80,751
80,751
0
080,75180,75180,75180,75180,75180,75180,75180,75180,75180,75180,75180,75180,75280,75280,75280,75266,58466,58466,58427,25427,25427,25427,25427,25427,25427,25427,25427,25427,25466,58427,25427,25466,58466,58466,58427,25427,25427,2543,6423,6422,8222,822133
   Retained Earnings 
7,429
10,423
10,966
12,265
14,519
17,561
22,856
25,369
24,690
24,690
16,669
24,452
12,975
13,356
16,863
26,432
21,352
24,255
30,504
29,537
29,392
32,956
53,273
122,876
110,250
86,870
103,289
115,573
135,917
83,834
89,372
-71,520
-338,266
-368,480
-388,342
6,420
-12,206
36,813
172,675
494,981
459,822
545,360
518,403
591,464
591,464518,403545,360459,822494,981172,67536,813-12,2066,420-388,342-368,480-338,266-71,52089,37283,834135,917115,573103,28986,870110,250122,87653,27332,95629,39229,53730,50424,25521,35226,43216,86313,35612,97524,45216,66924,69024,69025,36922,85617,56114,51912,26510,96610,4237,429
   Capital Surplus 00000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
316,146
361,582
373,046
463,986
846,328
883,139
961,737
1,036,270
1,284,478
1,424,085
1,458,905
1,564,253
0
01,564,2531,458,9051,424,0851,284,4781,036,270961,737883,139846,328463,986373,046361,582316,1460000000000000000000000000000000



Cash Flow

Currency in ARS. All numbers in thousands.




Income Statement

Currency in ARS. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue16,615,676
Cost of Revenue-11,686,598
Gross Profit4,929,0784,929,078
 
Operating Income (+$)
Gross Profit4,929,078
Operating Expense-14,293,099
Operating Income2,322,577-9,364,021
 
Operating Expense (+$)
Research Development-
Selling General Administrative951,099
Selling And Marketing Expenses-
Operating Expense14,293,099951,099
 
Net Interest Income (+$)
Interest Income-
Interest Expense-744,857
Net Interest Income-744,857-744,857
 
Pretax Income (+$)
Operating Income2,322,577
Net Interest Income-744,857
Other Non-Operating Income Expenses-
Income Before Tax (EBT)1,417,4462,322,577
EBIT - interestExpense = -744,857
591,464
1,336,321
Interest Expense744,857
Earnings Before Interest and Taxes (ebit)-2,162,302
Earnings Before Interest and Taxes (ebitda)2,507,899
 
After tax Income (+$)
Income Before Tax1,417,446
Tax Provision-816,014
Net Income From Continuing Ops601,432601,432
Net Income591,464
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-744,857
 

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.

Comments

Join the conversation.

Leave a comment
Penke's Market Notifications